Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Armando B D Djiyou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Agence Nationale de Recherches sur le Sida et les hepatites virales.
Abstract (Originalsprache)
Objectives
To characterize HIV drug resistance (HIVDR) below and above the WHO threshold of 1000 copies/mL, considered for the definition of HIV ART failure in resource-limited settings.
Methods
From a cohort of 280 adolescents (aged 10–19 years) receiving ART for at least 6 months, genotypic resistance testing (GRT) was attempted for two groups of participants: participants with low-level viraemia [LLV; viral load (VL) 200–999 copies/mL] and those in virological failure (VF; confirmed VL ≥1000 copies/mL) using an in-house method. The Stanford HIValg Program was used to identify relevant HIVDR mutations and predict the efficacy of the newly introduced tenofovir-lamivudine-dolutegravir combination.
Results
GRT was successfully performed in 54/58 (93.1%) eligible participants, of which 28/31 (90.3%) were in VF and 26/27 (96.3%) had LLV. A high level of resistance was found both in adolescents with LLV and those in VF, with respectively 84.6% (22/26) and 75.0% (21/28) of participants harbouring at least one HIVDR mutation. NRTIs and NNRTIs were the most affected drug classes in both population groups. In contrast, PIs were not significantly affected and dolutegravir was expected to be active for all participants tested. However, for the newly introduced dolutegravir-based combination, functional monotherapy (dolutegravir only) was potentially possible for 22.7% (5/22) of the participants with LLV.
Conclusions
Our findings show that the 1000 copies/mL threshold is not an indicator of virological success and we call for a revision of the current WHO definition of VF in resource-limited countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
- MIVEGEC, Université de Montpellier, CNRS, IRD, Montpellier, France.
- Department of Clinical Sciences, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.
- Department of Pediatrics and Child Health, General Hospital of Douala, Douala, Cameroon.
- Institut Pasteur, Université de Paris, Epidemiology of Emerging Diseases, F-75015 Paris, France.
- Department of Virology, Hôpital Laquintinie, Douala, Cameroon.
ORCID-Profile: Avelin F Aghokeng
Förderung
- Agence Nationale de Recherches sur le Sida et les hepatites virales
Zitieren
APA
Djiyou, A. B. D., Penda, C. I., Madec, Y., Ngondi, G. D., Moukoko, A., Eboumbou, C. E., & Aghokeng, A. F. (2023). Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad334
Vancouver
Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Eboumbou CE, et al. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad334
BibTeX
@article{Djiyou2023,
author = {Djiyou, Armando B D and Penda, Calixte I and Madec, Yoann and Ngondi, Grace D and Moukoko, Astrid and Eboumbou, Carole E and Aghokeng, Avelin F},
title = {Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad334}
}
EUVIMED